Harnessing the immunomodulatory and tissue repair properties of mesenchymal stem cells to restore β cell function

Current Diabetes Reports

Volumn 12, Issue 5, 2012, Pages 612-622

  Davis, Nicolynn E ^a   Hamilton, Diana ^a   Fontaine, Magali J ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cell function; Immunomodulation; Immunomodulatory and tissue repair properties; Islet transplantation; Mesenchymal stem cells; Type 1 diabetes

Indexed keywords

5' NUCLEOTIDASE; BETA1 INTEGRIN; CD71 ANTIGEN; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR4; ENDOGLIN; FRACTALKINE; GALECTIN; GAMMA INTERFERON; GELATINASE A; GELATINASE B; HEME OXYGENASE 1; HERMES ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; NITRIC OXIDE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROSTAGLANDIN E2; SCATTER FACTOR; STROMAL CELL DERIVED FACTOR 1; THY 1 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CELL CONTACT; CELL EXPANSION; CELL INTERACTION; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CYTOKINE RELEASE; DENDRITIC CELL; HUMAN; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; MESENCHYMAL STEM CELL TRANSPLANTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PANCREAS ISLET TRANSPLANTATION; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVASCULARIZATION; THERAPY EFFECT; TISSUE REGENERATION; TISSUE REPAIR;

ANIMALS; DIABETES MELLITUS, TYPE 1; HUMANS; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS TRANSPLANTATION; MESENCHYMAL STROMAL CELLS;

EID: 84870839254     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-012-0305-4     Document Type: Article

References (112)

1. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:14-37
2. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8:726-36
3. Rafei M, Campeau PM, Aguilar-Mahecha A, et al. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J Immunol. 2009;182:5994-6002
4. Papadopoulou A, Yiangou M, Athanasiou E, et al. Mesenchymal stem cells are conditionally therapeutic in preclinical models of rheumatoid arthritis. Ann Rheum Dis. 2012
5. Choi EW, Shin IS, Park SY, et al. Reversal of serologic, immunologic, and histologic dysfunction in mice with systemic lupus erythematosus by long-term serial adipose tissue-derived mesenchymal stem cell transplantation. Arthritis Rheum. 2012;64:243-53
6. Ciccocioppo R, Bernardo ME, Sgarella A, et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising crohn's disease. Gut. 2011;60:788-98
7. Aksu AE, Horibe E, Sacks J, et al. Co-infusion of donor bone marrow with host mesenchymal stem cells treats gvhd and promotes vascularized skin allograft survival in rats. Clin Immunol. 2008;127:348-58
8. Fotino C, Ricordi C, Lauriola V, et al. Bone marrow-derived stem cell transplantation for the treatment of insulin-dependent diabetes. Rev Diabet Stud. 2010;7:144-57
9. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet. 2001;358:221-9 (Pubitemid 32718550)
10. Schlosser M, Koczwara K, Kenk H, et al. In insulinautoantibody-positive children from the general population, antibody affinity identifies those at high and low risk. Diabetologia. 2005;48:1830-2 (Pubitemid 41317837)
11. da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci. 2006;119:2204-13 (Pubitemid 43960310)
12. Friedenstein AJ, Gorskaja UF, Kulagina NN. Fibroblasts precursors in normal and irradiated mouse hematopoietic organs. Exp Hematol. 1976;4:267-74
13. Sakaguchi Y, Sekiya I, Yagishita K, et al. Suspended cells from trabecular bone b y collagenase digestion become virtually identical to mesenchymal stem cells o btained from marrow aspirates. Blood. 2004;104:2728-35 (Pubitemid 39434954)
14. Gronthos S, Zannettino ACW. A method to isolate and purify human bone marrow stromal stem cells. In: Prockop DJ, Phinney DG, Bunnell BA, editors. Methods in molecular biology. Humana Press Inc; 2008. p. 45-57
15. Walsh S, Jefferiss C, Stewart K, et al. Expression of the developmental markers Stro-1 and alkaline phosphatase in cultures of human marrow stromal cells: regulation by fibroblast growth factor (FGF)-2 and relationship to the expression of FGF receptors 1-4. Bone. 2000;27:185-95 (Pubitemid 30458810)
16. Ning H, Lin G, Lue TF, et al. Mesenchymal stem cell marker Stro-1 is a 75kd endothelial antigen. Biochem Biophys Res Commun. 2011;413:353-7
17. Horwitz EM, Le Blanc K, Dominici M, et al. Clarification of the nomenclature for MSC: the international society for cellular therapy position statement. Cytotherapy. 2005;7:393-5 (Pubitemid 41671625)
18. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy. 2006;8:315-7 (Pubitemid 44269669)
19. Chamberlain G, Fox J, Ashton B, et al. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells. 2007;25:2739-49 (Pubitemid 350127858)
20. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal c ells. Blood. 2007;110:3499-506 (Pubitemid 350159613)
21. Nauta AJ, Westerhuis G, Kruisselbrink AB, et al. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood. 2006;108:2114-20 (Pubitemid 44395028)
22. Fiorina P, Jurewicz M, Augello A, et al. Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol. 2009;183:993-1004
23. Madec AM, Mallone R, Afonso G, et al. Mesenchymal stem cells protect nod mice from diabetes by inducing regulatory T cells. Diabetologia. 2009;52:1391-9
24. Jurewicz M, Yang SM, Augello A, et al. Congenic mesenchymal stem cell therapy reverses hyperglycemia in experimental type 1 diabetes. Diabetes. 2010;59:3139-47
25. Abdi R, Fiorina P, Adra CN, et al. Immunomodulation by mesenchymal stem cells - a potential therapeutic strategy for type 1 diabetes. Diabetes. 2008;57:1759-67
26. Yagi H, Soto-Gutierrez A, Parekkadan B, et al. Mesenchymal stem cells: mechanisms of immunomodulation and homing. Cell Transplant. 2010;19:667-79
27. Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. 2002;30:42-8 (Pubitemid 34059216)
28. Le Blanc K, Tammik L, Sundberg B, et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol. 2003;57:11-20 (Pubitemid 38019084)
29. Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99:3838-43 (Pubitemid 34534559)
30. Ryan JM, Barry F, Murphy JM, et al. Interferon-γ does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol. 2007;149:353-63 (Pubitemid 47063057)
31. Zhao W, Wang Y, Wang DD, et al. TGF-beta expression by allogeneic bone marrow stromal cells ameliorates diabetes in nod mice through modulating the distribution of CD4+ T cell subsets. Cell Immunol. 2008;253:23-30
32. Tse WT, Pendleton JD, Beyer WM, et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplant. 2003;75:389-97 (Pubitemid 36222968)
33. Yanez R, Oviedo A, Aldea M, et al. Prostaglandin E2 plays a key role in the immunosuppressive properties of adipose and bone marrow tissue-derived mesenchymal stromal cells. Exp Cell Res. 2010;316:3109-23
34. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105:1815-22 (Pubitemid 40223708)
35. Chen L, Zhang W, Yue H, et al. Effects of human mesenchymal stem cells on the differentiation of dendritic cells from CD34+ cells. Stem Cells Dev. 2007;16:719-31 (Pubitemid 350125233)
36. English K, Ryan JM, Tobin L, et al. Cell contact, prostaglandin E (2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4 + CD25 (high) Forkhead Box P3+ regulatory T cells. Clin Exp Immunol. 2009;156:149-60
37. Duffy MM, Pindjakova J, Hanley SA, et al. Mesenchymal stem cell inhibition of T-helper 17 cell-differentiation is triggered by cell-cell contact and mediated by prostaglandin E2 via the EP4 receptor. Eur J Immunol. 2011;41:2840-51
38. Krampera M, Cosmi L, Angeli R, et al. Role for interferongamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells. 2006;24:386-98 (Pubitemid 44464808)
39. Meisel R, Zibert A, Laryea M, et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase mediated tryptophan degradation. Blood. 2004;103:4619-21 (Pubitemid 38745993)
40. Sato K, Ozaki K, Oh I, et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood. 2007;109:228-34 (Pubitemid 46053063)
41. Bingisser RM, Tilbrook PA, Holt PG, et al. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the JAK3/STAT5 signaling pathway. J Immunol. 1998;160:5729-34 (Pubitemid 28298028)
42. Glennie S, Soeiro I, Dyson PJ, et al. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood. 2005;105:2821-7 (Pubitemid 40446275)
43. Ding YC, Xu DM, Feng G, et al. Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and-9. Diabetes. 2009;58:1797-806
44. Sioud M. New insights into mesenchymal stromal cell-mediated T-cell suppression through galectins. Scand J Immunol. 2011;73:79-84
45. Perillo NL, Pace KE, Seilhamer JJ, et al. Apoptosis of T cells mediated by galectin-1. Nature. 1995;378:736-9 (Pubitemid 126647279)
46. Hsu DK, Chen HY, Liu FT. Galectin-3 regulates T-cell functions. Immunol Rev. 2009;230:114-27
47. Sioud M, Mobergslien A, Boudabous A, et al. Mesenchymal stem cell-mediated T cell suppression occurs through secreted galectins. Int J Oncol. 2011;38:385-90
48. Corcione A, Benvenuto F, Ferretti E, et al. Human mesenchymal stem cells modulate B-cell functions. Blood. 2006;107:367-72 (Pubitemid 43053565)
49. Sotiropoulou PA, Perez SA, Gritzapis AD, et al. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells. 2006;24:74-85
50. Jiang XX, Zhang Y, Liu B, et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood. 2005;105:4120-6 (Pubitemid 40656164)
51. Nauta AJ, Kruisselbrink AB, Lurvink E, et al. Mesenchymal stem cells inhibit generation and function of both CD34(+)-derived and monocyte-derived dendritic cells. J Immunol. 2006;177:2080-7 (Pubitemid 44200965)
52. Li FR, Wang XG, Deng CY, et al. Immune modulation of cotransplantation mesenchymal stem cells with islet on T and dendritic cells. Clin Exp Immunol. 2010;161:357-63
53. Ryan JM, Barry FP, Murphy JM, et al. Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond). 2005;2:8
54. Beyth S, Borovsky Z, Mevorach D, et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce Tcell unresponsiveness. Blood. 2005;105:2214-9 (Pubitemid 40731815)
55. English K, Barry FP, Mahon BP. Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation. Immunol Lett. 2008;115:50-8 (Pubitemid 350298590)
56. Augello A, Tasso R, Negrini SM, et al. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum. 2007;56:1175-86 (Pubitemid 46608642)
57. Yamazaki S, Bonito AJ, Spisek R, et al. Dendritic cells are specialized accessory cells along with TGF-beta for the differentiation of Foxp3(+) CD4(+) regulatory t cells from peripheral Foxp3(-) precursors. Blood. 2007;110:4293-302 (Pubitemid 351377794)
58. Peng YF, Laouar Y, Li MO, et al. TGF-beta regulates in vivo expansion of Foxp3-expressing CD4(+)CD25(+) regulatory T cells responsible for protection against diabetes. Proc Natl Acad Sci U S A. 2004;101:4572-7 (Pubitemid 38437452)
59. Tarbell KV, Petit L, Zuo XP, et al. Dendritic cell-expanded, isletspecific CD4(+) CD25(+) CD62L(+) regulatory T cells restore normoglycemia in diabetic nod mice. J Exp Med. 2007;204:191-201 (Pubitemid 46148769)
60. Tonkin DR, He J, Barbour G, et al. Regulatory T cells prevent transfer of type 1 diabetes in NOD mice only when their antigen is present in vivo. J Immunol. 2008;181:4516-22
61. Luo X, Yang H, Kim IS, et al. Systemic transforming growth factor-beta I gene therapy induces Foxp3 + regulatory cells, restores self-tolerance, and facilitates regeneration of beta cell function in overtly diabetic nonobese diabetic mice. Transplantation. 2005;79:1091-6 (Pubitemid 40664003)
62. Boumaza I, Srinivasan S, Witt WT, et al. Autologous bone marrow-derived rat mesenchymal stem cells promote Pdx-1 and insulin expression in the islets, alter T cell cytokine pattern and preserve regulatory T cells in the periphery and induce sustained normoglycemia. J Autoimmun. 2009;32:33-42
63. Engela AU, Baan CC, Peeters AM, et al. Interaction between adipose-tissue derived mesenchymal stem cells and regulatory T cells. Cell Transplant. 2012
64. Crop MJ, Baan CC, Korevaar SS, et al. Human adipose tissuederived mesenchymal stem cells induce explosive T-cell proliferation. Stem Cells Dev. 2010;19:1843-53
65. Casiraghi F, Azzollini N, Cassis P, et al. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol. 2008;181:3933-46
66. Berman DM, Willman MA, Han DM, et al. Mesenchymal stem cells enhance allogeneic islet engraftment in nonhuman primates. Diabetes. 2010;59:2558-68
67. Solari MG, Srinivasan S, Boumaza I, et al. Marginal mass islet transplantation with autologous mesenchymal stem cells promotes long-term islet allograft survival and sustained normoglycemia. J Autoimmun. 2009;32:116-24
68. Ortiz LA, Gambelli F, McBride C, et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci U S A. 2003;100:8407-11 (Pubitemid 36842558)
69. Barbash IM, Chouraqui P, Baron J, et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium -feasibility, cell migration, and body distribution. Circulation. 2003;108:863-8 (Pubitemid 37022130)
70. Lin P, Chen L, Li D, et al. Dynamic analysis of bone marrow mesenchymal stem cells migrating to pancreatic islets using coculture microfluidic chips: an accelerated migrating rate and better survival of pancreatic islets were revealed. Neuroendocrinol Lett. 2009;30:204-8
71. Lee RH, Seo MJ, Reger RL, et al. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/SCID mice. Proc Natl Acad Sci U S A. 2006;103:17438-43 (Pubitemid 44788987)
72. Sordi V, Malosio ML, Marchesi F, et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood. 2005;106:419-27 (Pubitemid 40981232)
73. Bell GI, Broughton HC, Levac KD, et al. Transplanted human bone marrow rogenitor subtypes stimulate endogenous islet regeneration and revascularization. Stem Cells Dev. 2012;21:97-109
74. Ezquer FE, Ezquer ME, Parrau DB, et al. Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type I diabetic mice. Biol Blood Marrow Transplant. 2008;14:631-40
75. Si Y, Zhao Y, Hao H, et al. Infusion of mesenchymal stem cells ameliorates hyperglycemia in type 2 diabetic rats. Diabetes. 2012;61:1616-25
76. Lu S, Lu C, Han Q, et al. Adipose-derived mesenchymal stem cells protect Pc12 cells from glutamate excitotoxicity-induced apoptosis by upregulation of Xiap through Pi3-k/Akt activation. Toxicology. 2011;279:189-95
77. Caja L, Bertran E, Campbell J, et al. The transforming growth factor-beta (TGF-beta) mediates acquisition of a mesenchymal stem cell-like phenotype in human liver cells. J Cell Physiol. 2011;226:1214-23
78. Park KS, Kim YS, Kim JH, et al. Trophic molecules derived from human mesenchymal stem cells enhance survival, function, and angiogenesis of isolated islets after transplantation. Transplantation. 2010;89:509-17
79. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem. 2006;98:1076-84 (Pubitemid 44128350)
80. Park KS, Kim YS, Kim JH, et al. Influence of human allogenic bone marrow and cord blood-derived mesenchymal stem cell secreting trophic factors on ATP (adenosine-5′-triphosphate)/ADP (adenosine-5′-diphosphate) ratio and insulin secretory function of isolated human islets from cadaveric donor. Transplant Proc. 2009;41:3813-8
81. Lu Y, Jin X, Chen Y, et al. Mesenchymal stem cells protect islets from hypoxia/reoxygenation-induced injury. Cell Biochem Funct. 2010;28:637-43
82. Choi SE, Choi KM, Yoon IH, et al. IL-6 protects pancreatic islet beta cells from pro-inflammatory cytokines-induced cell death and functional impairment in vitro and in vivo. Transpl Immunol. 2004;13:43-53
83. Ogawa M, Nishiura T, Oritani K, et al. Cytokines prevent dexamethasone-induced apoptosis via the activation of mitogenactivated protein kinase and phosphatidylinositol 3-kinase pathways in a new multiple myeloma cell line. Cancer Res. 2000;60:4262-9 (Pubitemid 30636615)
84. Emamaullee JA, Rajotte RV, Liston P, et al. Xiap overexpression in human islets prevents early posttransplant apoptosis and reduces the islet mass needed to treat diabetes. Diabetes. 2005;54:2541-8 (Pubitemid 41233574)
85. Plesner A, Liston P, Tan R, et al. The x-linked inhibitor of apoptosis protein enhances survival of murine islet allografts. Diabetes. 2005;54:2533-40 (Pubitemid 41235478)
86. Vasavada RC, Gonzalez-Pertusa JA, Fujinaka Y, et al. Growth factors and beta cell replication. Int J Biochem Cell Biol. 2006;38:931-50 (Pubitemid 43363423)
87. Nakano M, Yasunami Y, Maki T, et al. Hepatocyte growth factor is essential for amelioration of hyperglycemia in streptozotocininduced diabetic mice receiving a marginal mass of intrahepatic islet grafts. Transplantation. 2000;69:214-21 (Pubitemid 30075277)
88. Otonkoski T, Beattie GM, Rubin JS, et al. Hepatocyte growthfactor scatter factor has insulinotropic activity in human fetal pancreatic-cells. Diabetes. 1994;43:947-53 (Pubitemid 24196430)
89. Kayali AG,VanGunstK, Campbell IL, et al. The stromal cell-derived factor-1 Alpha/CXCR4 ligand-receptor axis is critical for progenitor survival andmigration in the pancreas. J Cell Biol. 2003;163:859-69 (Pubitemid 37517892)
90. Kinnaird T, Stabile E, Burnett MS, et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circul Res. 2004;94:678-85 (Pubitemid 38387752)
91. Cheng Y, Liu YF, Zhang JL, et al. Elevated vascular endothelial growth factor production and its effect on revascularization and function of graft islets in diabetic rats. World J Gastroenterol. 2007;13:2862-6 (Pubitemid 47007904)
92. Figliuzzi M, Cornolti R, Perico N, et al. Bone marrow-derived mesenchymal stem cells improve islet graft function in diabetic rats. Transplant Proc. 2009;41:1797-800
93. Ito T, Itakura S, Todorov I, et al. Mesenchymal stem cell and islet co-transplantation promotes graft revascularization and function. Transplantation. 2010;89:1438-45
94. Rackham CL, Chagastelles PC, Nardi NB, et al. Co-transplantation of mesenchymal stem cells maintains islet organisation and morphology in mice. Diabetologia. 2011;54:1127-35
95. Johansson U, Rasmusson I, Niclou SP, et al. Formation of composite endothelial cell-mesenchymal stem cell islets - a novel approach to promote islet revascularization. Diabetes. 2008;57:2393-401
96. Neeman Z, Hirshberg B, Harlan D, et al. Radiologic aspects of islet cell transplantation. Curr Diab Rep. 2006;6:310-5 (Pubitemid 44322703)
97. Juang JH, Hsu BRS, Kuo CH. Islet transplantation at subcutaneous and intramuscular sites. Transplant Proc. 2005;37:3479-81
98. Kemp CB, Knight MJ, Scharp DW, et al. Effect of transplantation site on the results of pancreatic islet isografts in diabetic rats. Diabetologia. 1973;9:486-91
99. Juang JH, Bonner-Weir S, Ogawa Y, et al. Outcome of subcutaneous islet transplantation improved by polymer device. Transplantation. 1996;61:1557-61 (Pubitemid 26190894)
100. Kawakami Y, Iwata H, Gu Y, et al. Modified subcutaneous tissue with neovascularization is useful as the site for pancreatic islet transplantation. Cell Transplant. 2000;9:729-32 (Pubitemid 32002584)
101. Stendahl JC, Wang LJ, Chow LW, et al. Growth factor delivery from self-assembling nanofibers to facilitate islet transplantation. Transplantation. 2008;86:478-81
102. Su J, Hu BH, Lowe WL, et al. Anti-inflammatory peptidefunctionalized hydrogels for insulin-secreting cell encapsulation. Biomaterials. 2010;31:308-14
103. Pileggi A, Molano RD, Ricordi C, et al. Reversal of diabetes by pancreatic islet transplantation into a subcutaneous, neovascularized device. Transplantation. 2006;81:1318-24 (Pubitemid 43804553)
104. Ashcroft Frances M, Rorsman P. Diabetes mellitus and the β cell: the last ten years. Cell. 2012;148:1160-71
105. Jiang R, Han Z, Zhuo G, et al. Transplantation of placentaderived mesenchymal stem cells in type 2 diabetes: a pilot study. Front Med. 2011;5:94-100
106. Estrada EJ, Valacchi F, Nicora E, et al. Combined treatment of intrapancreatic autologous bone marrow stem cells and hyperbaric oxygen in type 2 diabetes mellitus. Cell Transplant. 2008;17:1295-304
107. Zisman A, Peroni OD, Abel ED, et al. Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance. Nat Med. 2000;6:924-8 (Pubitemid 30644753)
108. Bernardo ME, Zaffaroni N, Novara F, et al. Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res. 2007;67:9142-9 (Pubitemid 47535900)
109. Rubio D, Garcia S, Paz MF, et al. Molecular characterization of spontaneous esenchymal stem cell transformation. PLoS One. 2008;3:e1398
110. Wang M, Yang Y, Yang D, et al. The immunomodulatory activity of human umbilical cord blood-derived mesenchymal stem cells in vitro. Immunology. 2009;126:220-32
111. Kang JW, Kang KS, Koo HC, et al. Soluble factors-mediated immunomodulatory effects of canine adipose tissue-derived mesenchymal stem cells. Stem Cells Dev. 2008;17:681-93
112. Veriter S, Aouassar N, Adnet PY, et al. The impact of hyperglycemia and the presence of encapsulated islets on oxygenation within a bioartificial pancreas in the presence of mesenchymal stem cells in a diabetic wistar rat model. Biomaterials. 2011;32:5945-56.